In this context, berberine effectively suppressed DLBCL cancer cells growth by inhibiting the MYC-driven downstream effector PCYT1A, and inducing mitophagy-dependent necroptosis [119], thus being eventually considered as a promising anticancer agent to treat MYC-overexpressing lymphomas. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.